当前位置: X-MOL 学术Nat. Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discovery through clinical sequencing in oncology
Nature Cancer ( IF 22.7 ) Pub Date : 2020-08-10 , DOI: 10.1038/s43018-020-0100-0
Mark T A Donoghue 1 , Alison M Schram 2 , David M Hyman 2, 3, 4 , Barry S Taylor 1, 3, 5, 6
Affiliation  

The molecular characterization of tumors now informs clinical cancer care for many patients. This advent of molecular oncology has been driven by the expanding number of therapeutic biomarkers that can predict sensitivity to both approved agents and investigational agents. Beyond its role in driving clinical-trial enrollments and guiding therapy in individual patients, large-scale clinical genomics in oncology also represents a rapidly expanding research resource for translational scientific discovery. Here we review the progress, opportunities, and challenges of scientific and translational discovery from prospective clinical genomic screening programs now routinely conducted for patients with cancer.



中文翻译:

通过肿瘤学临床测序发现

肿瘤的分子特征现在为许多患者的临床癌症护理提供信息。分子肿瘤学的出现是由越来越多的治疗性生物标志物推动的,这些标志物可以预测对已批准药物和研究药物的敏感性。除了在推动临床试验注册和指导个体患者治疗方面的作用外,肿瘤学中的大规模临床基因组学还代表了快速扩展的转化科学发现研究资源。在这里,我们回顾了现在常规为癌症患者进行的前瞻性临床基因组筛查项目的科学和转化发现的进展、机遇和挑战。

更新日期:2020-08-10
down
wechat
bug